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ABSTRACT 
The clinicopathologic features of liver allograft dysfunction occurring in 51 symptomatic 
recipients after more than 5 years survival (mean 7.1 years) with the same hepatic allograft was 
compared to a similar group of 14 asymptomatic patients (mean survival 9.9 years), who 
underwent a non-clinically indicated protocol liver biopsy evaluation. Predictably, patients who 
had clinically indicated biopsies more frequently showed histopathologic alterations (76% vs. 
36%, p < 0.002). After detailed clinicopathologic correlation the changes in the symptomatic 
patients were primarily attributed to definite or presumed viral hepatitis in J 7/51 (33%) patients, 
11 of whom had recurrent viral disease; non-viral recurrent original disease in 7/51 (14%), 
obstructive cholangiopathy 3/51(6%), and acute cellular andlor chronic rejection 11151 (22%) 
patients. In 13/51 (25%) of the symptomatic patients the clinical and pathologic abnormalities 
were minimal. Long term liver allograft survival in 9114 (64%) of the asymptomatic patients was 
associated with minimally abnormal histologic alterations. Two of the asymptomatic patients had 
obstructive cholangiopathy, two others recurrence of the original disease and one possible viral 
hepatitis. Viral hepatitis types Band C, alcoholic liver disease, autoimmune hepatitis, 
granulomatous hepatitis (NOS), and probably primary biliary cirrhosi: (PBC) and primary 
sclerosing cholangitis (PSC) were shown to recur after hepatic transplantation. 
The histopathologic changes associated with acute cellular and chronic rejection frequently 
overlapped with other syndromes causing late dysfunction, such as chronic viral or autoimmune 
hepatitis, PBC or PSC and more than one insult could be identified in 15 of the cases, which 
made the differential diagnosis of causes of late liver allograft dysfunction much more difficult 
._--_ .. _ ..• _._._---
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than early after hepatic transplantation. It is important to correlate the biopsy findings with the 
liver injury tests, the results of viral and autoimmune antibody serologic studies, review of 
previous biopsies, and to be aware of the original disease, recent changes in immunosuppression 
and results of therapeutic intervention(s) in order to correctly identify the causes of liver allograft 
dysfunction in this patient population. 
Key words: Liver transplantation, histopathology, late dysfunction, diagnosis, tolerance, recurrent 
disease, alcoholism, hepatitis 
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INTRODUCTION 
Orthotopic liver transplantation is now a well accepted form of therapy for patients with 
endstage liver disease4o. Many large centers report patient survival rates which range from 70-
90% at one year and there is a more gradual attrition or even flattening of allograft and patient 
survival curves after 2-3 years, compared to kidney or heart allografts where progressive 
deterioration because of rejection is the rule. However, long term morbidity and allograft 
dysfunction are not uncommon, so that an increasing number of physicians will be faced with 
the problem of correctly identifying and then treating liver allograft dysfunction in their patient 
population, guided by a core needle biopsy and other laboratory or diagnostic tests. 
While the clinical and histopathologic features of early « 2 years) causes of liver allograft 
dysfunction are well described6.l0,]2,]4,2],23,25,33.34.38.39,44,46,47 those associated with late dysfunction 
are more limited in scope3,5,7,]3,] 7,] 8,]9,22,27,29,30,31,35,37 and few studies specifically address the 
problems associated with a clinicopathologic differential diagnosis III long-term 
survivors3,5,7,]5,]7,]9,22,27,35. None have reviewed the material from patients surviving for more than 
5 years. Moreover, recognizing baseline changes in long-surviving allografts is important for 
differential diagnosis and in immunosuppressive drug withdrawal trials31 ,36. The following study 
is designed with two goals in mind: a) to identify the histopathologic features and causes of late 
liver allograft dysfunction; and b) to determine if long term, stable allograft livers in patients 
without clinical signs or symptoms of dysfunction develop any histopathologic changes 
attributable to prolonged engraftment that would otherwise not be present in age-matched 
controls. 
--_._.-._--, .... ---_.,'._ .... ,-_. 
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MATERIALS AND METHODS 
Patient Selection 
One thousand eight hundred and thirty-three liver transplant operations were completed 
III 1431 patients (686 males and 745 females) at the University of Colorado or University of 
Pittsburgh before Dec. 31, 1988. The cumulative five year patient and allograft survival rates 
were 65% and 50%, respectively, for females, and 58% and 43%, respectively, for males(p< 
0.012 for patient and p < 0.0062 for allograft survival; female vs male; log-rank test). Of the 
long term survivors, 51/174 who have undergone liver biopsy evaluation for hepatic injury or 
dysfunction occurring more than 5 years after transplantation were randomly chosen from an in-
house computerized database. Hereafter, these 51 patients who underwent indicated biopsies will 
be called the "symptomatic" group; it consisted of 32 females and 19 males, with an average age 
of 42.8 years (range 23-65 years) and a mean survival of 7.1 years at the time of biopsy (Table 
1). The age and distribution of original disease was representative of the total group of long term 
survivors. An additional 14 "asymptomatic" patients were randomly selected from a group of 59 
patients, who were well, survived for an average of 9.9 years (range 5-16 years) with the same 
liver and underwent liver protocol biopsy evaluation to test for hematolymphoid chimerism.41 
There were 10 females and 4 males in this group, with an average age of 45.7 years (range 25-69 
years). One patient was initially classified as asymptomatic but later was found to have had signs 
and symptoms of allograft dysfunction and switched to the "symptomatic" group. 
Complete information about the donor age (average age 21; range 11-3 9 years), sex 
(27=M; 24=F), ABO blood group, HLA type and. crossmatch was available in 56 of the 65 total 
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patients and showed no significant differences between the two groups. 
Backtable biopsies obtained from twenty donors who died because of a cerebrovascular 
accident (n=9), motor vehicle accident (n=4) or other trauma (n=7) served as normal controls. 
None had known history of liver disease and serologic studies for HBV, HCV and mv were 
negative. 
Immunosuppressive Regimens 
All of the patients originally received a combination of cyclosporin A (Sandoz, Basel, 
Switzerland) and corticosteroids as baseline immunosuppression; twelve (12) of the patients also 
received azathioprine (ImuranR, Burroughs Wellcome, Research Triangle Park, NC). Rejection 
episodes generally were treated with a 1 gram "bolus" of methylprednisolone or a tapering 
"recycle" of prednisone. "Steroid-resistant" rejection episodes were treated with a 3-10 day 
course of OKT3 (Ortho Pharmaceuticals, Raritan, NJ). Twenty five of the patients in the 
symptomatic group but no asymptomatic patients were switched from a baseline 
immunosuppression of Cy A to FK506 (Fujisawa Pharmaceuticals, Japan) from 2-10 years after 
transplantation for acute cellular or chronic rejection4 (n= 18), Cy A toxicity (n=5) or viral hepatitis 
(n=2). Two of the asymptomatic patients have subsequently been completely weaned from all 
immunosuppressive drugs for 6-8 months without experiencing rejection. 
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Histopathologic Studies 
All patients were followed until 06/01/93 and any biopsy or failed allograft obtained from 
these patients after >5 years survival with the same liver and before 06/01/93 was reviewed. 
There were 106 needle biopsies and 6 allograft hepatectomy specimens obtained between 5 and 
18 years after transplantation. The slides were reviewed together by two of the authors (OP, 
AID) in a systematic fashion, without knowledge of the indication for biopsy, liver injury tests, 
viral serologic data, clinical events or original disease. The histopathokgic features listed on 
Table 2 were assessed, the results recorded and a histopathologic diagnosis(es) rendered. When 
more than one diagnosis was given, they were listed in order of importance with the one 
perceived to be the most significant listed first. A chi-squared exact test was used to compare 
the frequency of histopathologic findings between two different groups: the first comparison was 
between symptomatic and asymptomatic patients; the second between seronegative patients and 
those who were either HBsAg+ or anti-Hey positive, using second generation RIBA assays. 
Clinicopathologic Determination of Cause of Allograft Dysfunction 
The original diagnosis was based only on the observed histopathologic parameters. The 
final retrospective diagnosis( es) was based on the histopathologic findings, and the clinical 
profile, serologic data, and if given, response to therapy including follow-up biopsies. All of the 
patients had at least 6 months of follow-up after the index biopsy and post-transplant serologic 
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studies for HBV and Hev were available in 59/65 patients. 
RESULTS 
Clinicopathologic Events Before 5 Years after Transplantation 
At the time of study, the primary liver allograft was in place for more than 5 years in 
42/51 (82%) of the symptomatic patients and in all of the asymptomatic patients. The second 
6/51 (12%) or third 3/51 (6%) allograft had functioned for> 5 years in the remaining 
symptomatic patients. The causes of previous allograft failure(s) in the 9 symptomatic patients 
who had non-primary allografts in place for more than 5 years included cellular rejection (n=4), 
chronic rejection (n=2), primary dysfunction (n=2) and a massive biopsy-induced subcapsular 
hematoma (n= 1). Thr~e of these patients required a third liver allograft because of chronic 
rejection (n=2) and a combination of ischemic injury and severe CMV hepatitis (n=I). All of 
the patients in both groups experienced at least one episode (range 1-5; mean 2 ± 1) of 
histopathologically documented acute cellular rejection in the studied allograft within the first five 
years after transplantation. 
Other significant events noted during the first 5 years of followup in these patients 
included: eighteen of the symptomatic and one asymptomatic patient required reconstruction 
and/or balloon dilatation of the biliary tree for strictures or obstruction; three symptomatic 
patients developed endstage kidney disease because of cyclosporine toxicity and underwent renal 
9 
transplantation; two other symptomatic patients developed an Epstein-Barr Virus (EBV)related 
lymphoproliferative disorder, one of which resolved while the other evolved into Hodgkin's 
Disease28, that was successfully treated with a MOPP regimen of chemotherapy. 
Patient and Allograft Survival after Five Years 
All but two of the symptomatic patients currently are alive, 5-18 years after 
transplantation. One died from sepsis and multiorgan failure while awaiting hepatic 
retransplantation, 2275 days after her first liver allograft had been destroyed by hepatic artery 
thrombosis and subsequent sepsis. The second patient died of bleeding esophageal varices 6631 
days after his first allograft became cirrhotic because of recurrent chronic HCV infection. All 
of the asymptomatic patients are alive with their original allograft an average of 9.9 years (range 
5-16 years) after transplantation. 
There were 6 failed allografts removed at the time of hepatic retransplantation from the 
symptomatic group of patients between 6 and 10 years survival with the same liver (mean=7 
years). Chronic rejection was the insult solely responsible for allograft failure in 3 of the 
patients, two of whom also had superimposed hepatic artery thrombosis. In one other, both 
chronic rejection and hepatitis B contributed to allograft failure. Changes suggestive of recurrent 
primary sclerosing cholangitis were seen in one (see below), and a combination of chronic HeV 
hepatitis and portal vein thrombosis destroyed the allograft in the final patient. 
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Signs and Symptoms of Late Liver Allograft Dysfunction 
In most recipients monitoring of liver allograft function included: bimonthly tests for 
biochemical evidence of liver inj ury, yearly viral hepatitis serology screens and yearly physical 
exams. The most common sign of late liver allograft dysfunction was an elevation of the liver 
injury test above baseline values for that patient, which included: 1) jaundice or total bilirubin 
> 2mg/dl; 2) increased canalicular enzymes (ALP and y-GTP) or transminases greater than 50% 
over the lowest value in the preceding month. In total, 19/51 (37%) of the patients who had 
indicated biopsies also had at least one of the following symptoms: fever (5/51; 10%); abdominal 
pain, nausea, vomiting or loss of appetite (9/51; 18%) or jaundice (7/51; 14%). In the more ill 
patients, the presenting symptoms at the time of biopsy included gastrointestinal bleeding 
(2/51;4%), and confusion and lethargy (4/51; 8%). 
Histopathologic Findings 
Piecemeal necrosis, bile duct loss, thickened plates, lobular disarray, hepatocyte necrosis, 
lobular inflammation, Kupffer's cell hypertrophy and cholestasis (Table 2) were the 
histopathologic changes present in a higher incidence in biopsies from the symptomatic patients 
(p < 0.002), when compared to biopsies from the asymptomatic patients. The changes present 
in a higher incidence in biopsies from HBV andlor HeV seropositive patients than in 
seronegative patients included piecemeal necrOSIS, bridging fibrosis, bile duct 
inflammationldamage and lobular disarray, hepatocyte necroSIS, lobular iilflammation and 
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Kupffer's cell hypertrophy (Table 2) . 
In general, the portal inflammation tended to be slightly more intense in the symptomatic 
patients, but in both groups consisted of lymphocytes, macrophages and fewer plasma cells. 
Eosinophils were much less common than early after transplantation, being present in 2114 (14%) 
of asymptomatic and 6/51 (12%) of the symptomatic patients. 
Clinicopathologic Diagnosis of Late Dysfunction 
The final retrospective diagnosis showed that viral hepatitis and recurrence of the original 
disease accounted for 47% of the episodes of allograft dysfunction occurring more than 5 years 
after transplantation (Table 3). In another 13/51 (25%) symptomatic patients the clinical and 
pathologic findings were minimal and no specific diagnosis was given. Acute cellular and/or 
chronic rejection accounted for 22% of late dysfunction syndromes, although another 16% of 
patients were thought to have acute cellular rejection as a secondary diagnosis. The remaining 
3 (6%) patients had obstructive cholangiopathy. The results of the liver injury tests obtained at 
the time of biopsy, segregated according to the primary final clinicopathologic diagnosis is shown 
in Table 4. The clinical and pathologic features of each of the causes of dysfunction are 
discussed in greater detail below. 
Rejection: Acute cellular rejection was the primary pathologic diagnosis in 2/51 (4%) patients 
and the secondary diagnosis in 8/51 (16%) others, all of whom were from the symptomatic group 
and ~howed non-selective, concomitant elevations of liver injury tests (Table 4). The 
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histopathologic characteristics were similar to those seen early after transplantation and included 
a predominantly mononuclear but mixed portal inflammatory infiltrate, with bile duct damage 
and/or central vein phlebitis (Figure 1). Subendothelial inflammation of portal or central veins 
was not observed, and periportal hepatocellular necrosis, spotty hepatocyte necrosis and lobular 
regenerative activity was more prominent than in cellular rej ection seen early after transplantation 
(personal observation, Figure 1). Lobular disarray as a manifestation of acute cellular rejection 
alone was distinctly unusual. The primary diagnosis in the 8 patients with acute cellular rejection 
as a secondary diagnosis was chronic rejection (n=3; see below), chronic hepatitis (n=4; 2 HCY, 
2 NANBNC) and minimal change (n=I). 
Chronic rejection was the primary histopathologic diagnosis in 9/51 (18%) patients all of 
whom were symptomatic, usually because of a preferential elevation of y-glutamyltranspeptidase 
and alkaline phosphatase (see Table 4). One patient also had cholangiographic evidence of 
intrahepatic biliary tract strictures. Histopathologic changes included mild chronic portal 
inflammation, hyalinization of the portal tract connective tissue, bile duct loss in > 25% of the 
triads, and other biliary epithelial cell alterations which included eosinophilic transformation of 
the cytoplasm, an increased nuclear:cytoplasmic ratio because of nuclear enlargement, uneven 
spacing of the nuclei and change from a dense nuclear chromatin pattern to an open, reticular 
chromatin profile with the appearance of ilUcleoli. In the lobules, mild spotty lobular necrosis 
without significant lobular disarray, mild mixed sinusoidal inflammation, sinusoidal foam cell 
clusters (n=3), Kupffer's cell hypertrophy (n=9), occasional apoptotic bodies (n=4), cholestasis 
(n=4), and steatosis (n=2) were present. 
Followup of both patients witb a primary diagnosis of acute cellular rejection showed that 
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treatment with increased immunosuppression resulted in improved liver injury tests and decreased 
liver allograft inflammation on rebiopsy. Of those with a secondary diagnosis of acute cellular 
rejection (n=8), 2 required retransplantation because of chronic rejection, 1 improved clinically 
and biochemically after a switch to FK506 but a background of chronic rejection persisted, and 
one improved after treatment with corticosteroids. Two patients with a primary diagnosis of 
hepatitis but a secondary diagnosis of cellular rejection biochemically responded to increased 
immunosuppression. One spontaneously improved while another improved after interferon 
treatment. 
Three of the 9 patients with chronic rejection showed stable or improved liver injury tests 
after a switch to FK506. One patient developed intrahepatic bile duct strictures, one has stable 
elevation of liver injury tests, one required retransplantation because of chronic rejection, one 
non-compliant patient has shown worsening ofliver injury tests and three r8maining patients were 
accounted for above. 
Biliary Tract Complications: Obstructive cholangiopathy was the primary diagnosis in 5 
patients, three of whom were symptomatic. One of the "asymptomatic" patients had a long history 
of biliary tract anastomotic strictures. As expected, the liver injury tests in this group of patients 
showed a profile similar to chronic rejection, with a preferential concomitant elevation of the 
"canalicular" enzymes ALP and y-GTP, which were ~ 3X the minimally elevated levels of ALT 
and AST (Table 4). 
The histopathologic changes in this group of patients was similar or identical to those 
seen in non-allografted livers with bile duct obstruction or.stricturing, and confirmed by 
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cholangiography in all of the patients, three of whom were successfully treated with operative 
reconstruction and/or balloon dilatation of the biliary tree. 
Viral Hepatitis: Definite or presumed chronic viral hepatitis was the primary diagnosis in 17 
symptomatic and one asymptomatic patient, four of whom also had co-existent acute cellular 
rej ection as a secondary diagnosis. In II of these patients, the viral disease in the allograft 
represented a recurrence of the original disease: two had HBV, 7 HCV, and 2 were presumed 
to be non-A, non-B, non-C, because the same histopathologic findings were present in the 
original liver, and HBV, HCV and auto-antibody serologic studies were negative. Seven cases 
represented de novo hepatitis; one patient had HBV, 2 HCV and 4 were presumed to have non-A, 
non-B, non-C because of the histopathologic findings (see below) and lack of a sustained 
response to increased immunosuppression therapy. 
Liver injury tests in this group of patients showed minimal to marked but non-specific 
elevations of both hepatocellular (AL T and AST) and canalicular (ALP and y-GTP) enzymes. 
When the patients with co-existent cellular rejection were excluded, there was less of an increase 
in the canalicular enzymes. 
Histopathologic changes included chronic portal inflammation often with formation of 
lymphoid nodules, damage of only an occasional bile duct, no bile duct loss, minimal to marked 
piecemeal necrosis, minimal to moderate lobular disarray, inflammation, periportal or midzonal 
predominant macrovesicular steatosis, hepatocyte necrosis and lobular regenerative changes 
(Figure 2). Significant portal fibrosis was present in II of the patients, 8 of whom showed focal 
portal-portal or portal-central bridging. 
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Seven of the patients with hepatitis were placed on a-interferon (a-IFN), 5 of whom 
experienced clinical and biochemical improvement within 6 months of beginning therapy. 
However, one other patient treated with a-IFN died from variceal hemorrhaging and the last 
patient required hepatic retransplantation because of recurrent HBV induced cirrhosis, complicated 
with chronic rejection. Follow up in the 11 remaining patients not treated with a-IFN showed 
that after lowering immunosuppression 3 developed rejection (see above). One other patient 
developed bile duct strictures requiring balloon dilatation and one patient lost his allograft 
because of recurrent HeV and portal vein thrombosis. Two patients spontaneously improved 
without therapeutic intervention, one of whom serologically cleared HBsAg, which had been 
present for at least 3 years after transplantation. Three other patients showed chronic viral 
hepatitis with persistent low grade activity, whereas one progressively deteriorated because of 
hepatitis. The remaining patient was lost to follow-up. 
Minimal Chronic Changes, Not Otherwise Specified: There were 22 (13 symptomatic, 9 
asymptomatic) patients in whom the biopsy findings were minimal and could not be classified 
into a specific histopathologic diagnosis. All but 2 were seronegative for HBV and Hev 
infection. Even though this group of patients had normal, or only mildly abnormal liver injury 
tests, relatively subtle changes in their biopsies could be used to distinguish them from liver 
biopsies obtained from age matched normal controls, even when the pathologists were blinded 
as to the origin of the slides. 
Altogether a slight increase in mononuclear portal or perivenular inflammation was present 
III 15122 (68%), and portal arterial and arteriolar mural myocyte hypertrophylhyperplasia and 
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hyalinization in 12/22 (55%) (Figure 3). Mild and more subtle intralobular regenerative activity 
was identified in 18/22 (82%) patients and mostly characterized by thickening of the plates 
(Figure 4). Biliary epithelial cell alterations, similar, but not as advanced as those described for 
chronic rejection, were seen in 11122 (50%) patients. In 1122 (5%) more abnormal biliary 
epithelial alterations and portal inflammation were present, eliciting a secondary diagnosis of 
acute cellular rejection. 
Two biopsies from the clinically well patients with negative viral serologic studies and 
normal liver injury tests contained focally dense lymphocytic infiltrates, without any evidence of 
bile duct injury or piecemeal necrosis. No specific therapeutic intervention was undertaken in 
this group of patients and allograft function remained stable and good for at least 6 months after 
the biopsy. 
Recurrence of Original Disease 
Recrudesence of a chronic viral hepatitis was the most common recurrent disease, being 
responsible for 11118 (61 %) cases, all of whom were just described above in detail. Four patients 
had recurrent alcoholic liver disease, 1 probable autoimmune chronic active hepatitis and one 
granulomatous hepatitis, NOS. Two patients were suspected of developing reappearance of PSC 
and one PBC. Unfortunately, the design of this study did not afford the opportunity to assess the 
true incidence of recurrent disease. The histopathology and clinicopathologic correlation for each 
of these disorders is given in more detail below. 
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Alcoholic Liver Disease: Alcoholic relapse was strongly suspected as the primary cause of the 
liver histopathology in 3 symptomatic and one asymptomatic patient from the 7 total who 
underwent transplantation for this indication. They all were sero-negative for HBV or HCV virus 
infection and there was no other apparent explanation for the biopsy findings detailed below. 
Liver injury tests in this group of patients showed a selective rise in y-GTP without a 
concomitant increase in ALP (Table 4). However, the ALT:AST ratio was approximately l. 
Two of the four patients denied alcohol abuse, although one of these two had blood alcohol 
levels of 98 mg/dl at the time of hospitalization. The other patient experienced fluctuating levels 
of y-GTP between 150-420 lUlL without apparent cause, which spontaneously declined during 
hospitalization without specific intervention. The remaining two patients admitted to recidivism. 
The biopsy histopathology typical of 3/4 patients is shown in Figure 5. One of these 
patients also showed focal portal-central bridging fibrosis with early regenerative micronodularity, 
Mallory's hyaline and megamitochondria. 
Primary Biliary Cirrhosis: Probable recurrent primary biliary cirrhosis was diagnosed in a 60 
year old female, who was 1116 (6%) patients who underwent transplantation for this indication 
and shared one HLA B and one HLA DR locus with the female donor. The diagnosis was 
largely based on hepatic histopathology (Figure 6), since the liver injury tests were only 
transiently abnormal. Normal cholangiographic studies, PBC in the original liver, and the 
exclusion of acid-fast bacteria, fungal infection or drug reactions were then used to further 
substantiate the diagnosis. Serologic studies for anti-mitochondrial antibodies were presumed to 
be positive and not repeated, because of the previously reported near universal re-elevation of this 
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disease marker in PBC patients? The mildly abnormal liver injury tests spontaneously returned 
to normal shortly after biopsy and have since remained normal for more than 2 years. 
Primary Sclerosing Cholangitis: Recurrence of "primary" sclerosing cholangitis(PSC) was first 
suspected between 5-6 years after transplantation in 2/6 (33%) patients, both of whom also had 
a history of ulcerative colitis. One patient had a total colectomy before liver transplantation and 
the colitis remained active up to the present time in the other patient. Both patients had ABO 
identical donors, negative lymphocytotoxic crossmatch results, and an "obstructive" liver enzyme 
profile at presentation. There was no obvious technical or mechanical explanation for the 
strictures observed on cholangiographic studies, but neither case was felt to be radiographically 
"classic" for PSC. 
The liver biopsies showed changes suggestive of obstructive cholangiopathy, incI uding 
mild portal expansion because of mild portal fibrosis, and acute and chronic pericholangitis. The 
biliary epithelium showed atrophic changes with eosinophilic transformation of the cytoplasm. 
One of these patients who was suspected of being non-compliant, eventually required 
hepatic retransplantation after 7 years (Figure 7). 
Granulomatous Hepatitis: A 44 year old male with negative viral hepatitis and autoantibody 
serologic studies was asymptomatic when a liver biopsy obtained 9 years after transplantation 
showed portal fibrosis and 2 portal-based and several non-caseating intralobular granulomas, 
without bile duct involvement or loss. The original liver showed mixed micro- and macronodular 
cirrhosis, with numerous non-caseating granulomas. No micro-organisms could be identifit::d with, 
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special stains in either the native liver or the hepatic allograft biopsy specimen. Ultimately, no 
specific cause of the granulomatous hepatitis could be found and the case was classified as 
recurrent granulomatous hepatitis, not otherwise specified. 
Autoimmune Chronic Active Hepatitis: Late dysfunction was attributed to recurrent 
autoimmune chronic active hepatitis, in a 44 year old HLA B8 and DR3 positive male, who was 
negative for serologic evidence of HBV, but positive for anti-nuclear antibodies (ANA) before 
and after transplantation. The donor organ was matched for these disease-associated HLA 
antigens and a liver biopsy obtained 11 years after transplantation showed chronic portal 
inflammation with a prominent plasmacytic component, and active piecemeal necrosis without 
significant bile duct damage and no bile duct loss. However, antibodies to the HeV were 
detected 2 years after the biopsy was obtained. The final diagnosis was recurrent autoimmune 
and chronic HeV infection. 
Prospective versus Retrospective Diagnosis 
There were 11/65 (17%) cases where the final retrospective diagnosis was different from 
the original diagnosis. In 3 cases, an original diagnosis of mild acute cellular rejection was 
switched to viral hepatitis because of positive serologic studies and lack of a sustained response 
to additional steroid therapy. In one case, the converse was true, an original diagnosis of 
hepatitis was switched to acute cellular rejection. However, even in retrospect, in some cases the 
separation of hepatitis from acute cellular or even early chronic rejection was less than certain. 
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In 3 cases the original descriptive diagnosis(es) were replaced by firm diagnosis(es) of disease 
recurrence: [alcoholic (n=2); granulomatous hepatitis, (NOS n= 1 )], in 2 cases the possibility of 
both chronic rejection and biliary strictures was originally raised and later, evidence of chronic 
rejection could not be substantiated and the patient had PSC as an original disease. In one case, 
it was difficult to separate or determine if recurrent HeV or recurrent alcohol abuse was primarily 
responsible for dysfunction. And finally, an original diagnosis of hepatitis was replaced by one 
of obstructive cholangiopathy. 
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DISCUSSION 
The most common indication for liver allograft biopsy in patients who survive> 5 years 
with the same organ is elevated liver injury tests; 37% of patients present with physical 
symptoms. The histopathologic changes in this patient population can be attributed to viral 
hepatitis or recurrent original disease 47% of the time, while cellular and chronic rejection 
together account for only 22% of allograft dysfunction episodes, which is much different than 
early after transplantation. Evolution of the causes of dysfunction over time can be explained 
by the early manifestation of operative or preservation-related injuries, and the dynamic nature 
of the immunologic interface between the liver allograft and the recipient8.41 . 
Our findings are quite similar to those recorded by Nakhleh et al27 who studied liver 
allograft biopsies taken from recipients in the cyclosporine era who had survived an average of 
3-4 years after transplantation. Porter33 , who, working with Starzl42,43 did much of the pioneering 
work in liver transplant pathology, reported more chronic rejection and less hepatitis in a group 
of pediatric and adult patients from the pre-cydosporine era. Hubscher et al~2 and Eid l3 on the 
other hand, reported less rejection and more normal or minimally abnormal biopsies in a 
relatively large series of patients who had survived a median of 18 months and 12 months after 
transplantation, respectively. Differences in the profile of original diseases in the recipient 
populations, immunosuppressive regimens and study designs make it impossible to directly 
compare results, but more protocol biopsies in both of the later series and identification of 
patients with "isolated ductopenia" by Hubscher22 probably account for this seemingly small 
dispari ties. 
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The syndromes resulting in late liver allograft dysfunction frequently have 
overlapping histopathologic features; mononuclear or mixed portal inflammation with varying 
degrees of bile duct damage and piecemeal necrosis can be found in acute cellular and chronic 
rejection, PBC, chronic viral and autoimmune hepatitis. Such changes when mild, may even be 
non-specific, but in general, when the portal inflammation is mixed and is associated with 
damage of more than an occasional bile duct, and there is mononuclear infiltration in and around 
the connective tissue sheath of the terminal hepatic venules, a diagnosis of rejection is favored. 
Conversely, nodular portal lymphoid aggregates or portal inflammation associated with damage 
of only an occasional bile duct, lymphoplasmacytic portal inflammation directed at periportal 
hepatocytes (piecemeal necrosis), and lobular disarray and lobular inflammation are features in 
favor of a diagnosis of hepatitis. The usefulness of this paradigm is supported by previous 
studies5 and the correlation between the "blind" histopathologic readings and the serologic tests 
for HBV and HCV infection, but the final diagnosis must take into account all of the clinical and 
laboratory data. 
Even so, arriving at that final definitive diagnosis in a long term liver allograft recipient 
is even more difficult than early after liver transplantation and in the end, the diagnosis may still 
be left open to subjective judgment. For example, subendothelial inflammation of the portal or 
central veins and portal eosinophilia are fairly reliable rejection-related findings in the first 
several months. In long term recipients, portal eosinophils are present in many chronic 
inflammatory liver diseases and when present with mild ductular proliferation and adequate 
immunosuppressive levels, obstructive cholangiopathy should be first excluded. Endotheliitis is 
less often encountered in long term survivors with acute cellular rejection, and not at all ill 
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chronic rejection6,lO,14,18,21,23,25,27,30,34,38,39,44,46. The portal infiltrate associated with late acute cellular 
rejection also is often not well confined within the limits of the portal tracts as is seen early after 
transplantation making separation from chronic viral hepatitis more difficult. Moreover, the 
presence of a virus or autoantibodies does not provide immunity from rejection9 , and more than 
one process can simultaneously affect the allograft. Finally, reliance on serologic markers alone 
for detection of HCV infection may underestimate the total number of infected patients and add 
to the difficulties. 
Liver injury test profiles can assist in the differential diagnosis. Preferential elevation of 
the "canalicular" enzymes (ALP and y-GTP) was more frequently associated with chronic 
rejection and biliary tract obstruction. The 4 patients with alcoholic relapse showed isolated 
increases of y-GTP, without a concomitant rise of ALP, similar to alcoholics in the general 
population. Hepatitis on the other hand showed elevation of both AL T / AST and ALP Iy-GTP, 
but overlappinf? rejection and "cholestatic" forms of hepatitis likely contribute this non-specific 
pattern of enzyme elevation. It is the authors' opinion that clinicopathologic correlation, 
awareness of the original disease, review of previous biopsies, and monitoring the effect of 
therapeutic intervention(s), in addition to a careful review of the index biopsy, is important in 
arriving at the correct diagnosis (Table 5). Similar conclusions have been drawn by most 
investigators studying long term survivors3,5,7.13.17,18.19.22,27,29,30,31,35,37. In some instances, empiric 
increases of immunosuppression and follow-up data may be of value in establishing the diagnosis, 
and in fact, supported the validity of our final retrospective diagnosis. 
Viral hepatitis types Band C, alcohol-related injury, autoimmune and granulomatous 
hepatitis (NOS), and primary biliary cirrhosis appear histopathologically similar or identical to 
----------
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the same diseases in native livers and recur after transplantation. Reappearance of primary 
sclerosing cholangitis was strongly suspected since we could find no other cause of the biliary 
cirrhosis and large extrahepatic bile duct inflammation in an allograft which failed after 7 years, 
even when the gross and histopathologic examination was complete. In contrast to the report by 
Hubscher et al22 who showed a recurrence rate of 16% and in some cases severe allograft liver 
injury from PBC, the pathologic changes in the single patient in this series was minimal. We 
remain intrigued by this difference in the reported incidence of PBC recurrence and disease 
severity.7,22,32 It is likely related to the addition of azathioprine or to lower baseline cyclosporin 
levels. 7,22,32 
In 24% of symptomatic patients there was no identifiable clinical, serologic or 
histopathologic cause of the usually mild dysfunction. Biopsies from these patients were for the 
most part, indistinguishable from those obtained from the long term asymptomatic recipients. 
Frequent monitoring of liver injury tests, cr:;:,bined with a lower biopsy threshold, may account 
for the relatively high frequency of biopsies with minimal pathologic changes. 
In contrast, there were two biopsies from asymptomatic, HCV and HBV negative patients 
with normal and stable liver injury tests, that contained significant chronic portal inflammation 
but no detectable tissue damage. Whether this represents very indolent: chronic NANBNC viral 
hepatitis, undetected hepatitis C virus infection, rejection or an immunologic adaptation of the 
recipient to the allograft similar to that seen in cardiac l (Quilty lesions) and renal"° allografts, is 
uncertain. The important message illustrated by such cases is that mononuclear inflammation 
alone in the absence of bile duct, vascular or hepatocyte damage can be associated with normal 
and stable liver allograft function and need not be treated with additional immunosuppression. 
25 
Therefore, a protocol biopsy before attempting to wean immunosuppressive therapy is strongly 
encouraged31.36.41. 
Many long term stable liver allografts develop histopathologic changes that are not 
otherwise present in age-matched controls, albeit they are minimal deviations from normal. 
Possible explanations for the mild lymphocytic inflammation were discussed above; the 
intrahepatic arteriolar changes can be seen as a result of diabetes, hypertension and perhaps direct 
drug related injury from chronic cyclosporine11 and corticosteroid therapy. The biliary epithelial 
cell and mild intralobular regenerative changes were far more subtle, the latter being insufficient 
for the diagnosis of nodular regenerative hyperplasia, a disorder originally described in patients 
with autoimmune diseases1, and later found with increased frequency after anabolic steroid and 
Azathioprine administration I 6.24.26. In this series, only 12/65 of the patients were maintained on 
Azathioprine and all were on either low dose, or no corticosteroids. Therefore, immunologically-
mediated perivenular or sinusoidal endothelial cell injury45 or other immunolm!ic perturbations 
in the recipient similar to that seen in autoimmune disorderss is a possible cause of the 
regeneration that cannot be dismissed out of hand. 
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TABLE 1. Patients and original disease at the time of transplantation. 
Asymptomatic Symptomatic 
FemalelMale 10/4 32/19 
Age (at time of transplant) 36.6 36.1 
Original Disease 
Primary bilial-Y Cirrhosis (PBC) 6 10 
Cryptogenic cirrhosis 1 8 
Alcoholic cilThosis 1 6 
Metabolic Diseases* 2 5 
Chronic HCV 2 5 
Primary Sclerosing Cholangitis 0 6 
Autoimmune Chronic Hepatitis 0 4 
Chronic HBV 0 4 
Other 1 3 
Fibrolamellar Carcinoma 1 
Total Number of Patients 14 51 
*Tyrosinemia and Porphyria (n=I), a-l-anti-TI-ypsin deficiency (n=I), Wilson's disease(n=4), 
Hemochromatosis( n=I). 
TABLE 2. Histopathologic changes categorized acce.rding to the reason for biopsy. 
SIm I!to.atic· p value Sel'ob+ p value 
Asymptomatic Sero -
PORTAL TRACT 
Inflammation: Mild 27/9<: 0.80 8/23 0.39 
Moderate 2114 7117 
Severe 3/1 0/4 
Eosinophils 6/2 0.80 2/5 1.0 
Piecemeal Necrosis 19/2 0.12 8111 0.01 
Bridging Fibrosis lOll 0.43 6/4 0.02 
Bile Duct Loss (> 25% of triads) 13/1 0.17 4/9 1.0 
Subendothelial inflammation 0/0 1.0 0/0 1.0 
Bile duct inflammation/damage 40/9 0.31 16127 0.006 
Ductularlcholangiolar proliferation 14/2 0.49 5/9 0.50 
LOBULE 
Thickened plates 50/11 0.03 15/40 1.0 
Disarray 15/1 0.16 11/4 0.0001 
Necrosis 2112 0.11 9112 0.07 
Inflammation 39/2 0.001 12125 0.13 
Kupffer cell hypertrophy 40/4 0.0009 14/26 0.06 
Cholestasis 12/1 0.27 3/7 1.0 
Fatty change 14/4 1.0 3114 0.35 
Hepato(:ytes anisonucleosis 19/4 0.75 3116 0.22 
Sinusoidal dilatation 10/3 1.0 1111 0.15 
Iron deposition 2/1 1.0 0/3 0.56 
VASCULAR 
Arteriolar thickeninglhyalinization 20/8 0.36 8118 0.77 
Obliterative arteriopathy 4/0 0.57 0/4 0.33 
Central vein phlebitis 13/3 1.00 3113 0.20 
Central vein sclerosis 1111 0.28 4/8 0.72 
Total number of patients 51114 16/43 
"A comparison of the histopatholgic findings in symptomatic versus asymptomatic patients. 
b A comparison of patients who were either seropositive for HbsAg or anti-HCV to those seronegative for both 
VlTuses. 
CMost of the portal inflammation in this group was minimaL 
TABLE 3. Breakdown offinal retrospective pl'imary clinicopathologic diagnoses in the symtomatic and 
asymptomatic patients. Patients are listed only by the primary diagnosis. 
CLINICOPATHOLOGIC DIAGNOSIS 
Cellular Rejection 
Chronic Rejection 
Obstructive Cholangiopathy 
Minimal Changes, NOS 
Viral Hepatitis 
HCV 
HBV 
NANBNC 
Recurrent Original Disease 
Alcoholic 
PSC 
PEC 
Autoimmune Hepatitis 
Granulomatous Hepatitis, NOS 
Viral Hepatitis (see above) 
Symptomatic l 
(no.=51) 
2 (4%) 
9 (18%) 
3 (6%) 
13 (25%) 
17 (35%) 
9 
3 
5 
18 (35%) 
3 
2 
1 
1 
11 
Asymptomatic2 
(no.=14) 
0(0%) 
0(0%) 
2 (14%) 
9 (64%) 
I ( 7%) 
1 
2 (14%) 
1 
Ipatients had clinical symptoms or elevated liver injury tests as an indication for biopsy. 
2Patients were asymptomatic and had normal liver injury tests; biopsies were done by protocol. 
TABLE 4. Liver injury test listed according to the primal")' clinicopathologic diagnosis. 
Diagnosis TBILI AST ALT ALP y-GTP 
Cmgldl) (lUlL) (lUlL) (lUlL) (lUlL) 
Cnl =0.3-1.5) (nl:;; 40) (nl :;; 40) (nl=40-125) (nl:;; 65) 
Minimal Changes 0.6:1: 0.3 I =:1: 62 100:1: 84 173 ± 114 246 ± 167 
(0.2-1.0) (13-264) (22-323) (74-573) (39-947) 
Obstructive 2.4:1:2.1 72 ± 25 73:1: 24 331 :I: 187 320:1: 167 
Cholangiopathy (0.8-7.3) (43-119) (46-292) 045-647) (119-635) 
Chronic Hepatitis 1.3 :I: 1.4 204 ± 214 193 ± 242 133 ± 76 237:1: 235 
(0.2-6.8) (35-895) (30-961 ) (21-239) (45-944) 
Alcohol injury 0.9:1: 0.2 99:1: 60 108:1: 62 89:1: 49 375 ± 245 
(0.7-1.2) (42-198) (56-226) (44-156) (178-705) 
1.1 ±0.9 116 :I: 97 90 :I: 61 194:1: 263 231 ± 205 
Cell ular Rej ection" (0.4 - 3.5) (11-314) (14 - 204) (39- 780) (77 - 628) 
Chronic Rejection 2.4 ± 2.2 113 ± 64 184 :I: 174 496 ± 360 736 ± 286 
(0.5 - 9.5) (45 - 229) (67 - 362) <.178 - 1192) (30 - 2270) 
..... ---------------------------------------------------.---------------------------------------------------.. -... ------------- .-----------. --_." .... -------------_ .... --------
"Includes patients with a primary and secondary diagnosis of acute cellular rejection. 
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FIGURE LEGENDS 
Figure 1. Acute cellular rejection in a patient who initially was "asymptomatic", then developed 
liver dysfunction as a result of immunosuppressive weaning. The portal tract (PT, inset) and 
peri-central vein (CV) inflammation and liver injury tests worsened after Cy A/steroid withdrawal 
and improved after restarting treatment. 
Figure 2. Chronic viral hepatitis type C often appeared histopathologically similar to that seen 
in non-transplanted livers as shown here, with lymphoid nodules in the portal triads, piecemeal 
necrosis, sinusoidal lymphocytosis and spotty lobular necrosis. In other cases of HeV, the 
inflammation was mild and neutrophilic predominant, but marked cholangiolar proliferation, more 
typical of a "cholestatic hepatitis" was seen. 
Figure 3. Hepatic arteriolar thickening and hyalinization, with intact bile ducts was seen III 
patients with minimal other changes and was attributed to hypertension, diabetes or chronic 
cyclosporin injury, similar to the lesions seen in the kidney. 
Figure 4. A) Mild intralobular regenerative activity, characterized by thickening of the plates 
and even focal nodule formation was a frequent but subtle finding in many of the long term 
survivors, even in those without symptoms or other pathologic changes. B) A reticulin stain 
shows the subtle areas of intralobular regenerative change with thickening of the plates. 
Figure 5. Recurrent alcohol abuse was most frequently (3/4 cases) associated with centrilobular 
mixed steatosis with "foamy" degeneration of hepatocytes (inset), lobular neutrophil clusters, 
perivenular and subsinusoidal fibrosis and Kupffer's cell iron deposition. One other patient who 
admitted to alcoholic relapse showed moderate reticuloendothelial iron deposition, portal and 
sinusoidal fibrosis, but no steatosis. As always, other causes of steatohepatitis should be 
excluded. 
Figure 6. This periductal granuloma with minimal duct damage was seen in a biopsy obtained 
6 years after transplantation in 1116 patients whose original disease was PBC and in no other 
patients, regardless of the original disease. 
Figure 7. Possible recurrent sclerosing cholangitis (with a component of rejection?) was 
suspected in this failed allograft (1100 gm) removed 7 years after transplantation. A) There was 
a well-developed biliary-type cirrhosis, with decreased bile ducts and deposition of copper-
associated protein at the edge of the regenerative nodules (inset), but no classic "fibro-
obliterative" duct lesions. B) Sections thrC'lllgh the liver hilum showed chronic inflammation of 
large bile ducts and mural fibrosis, but no obliterative arteriopathy. 
